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Abstract
Tissue biopsies are required for diagnosis, prognosis, and to measure individual drug
response markers for patient management. For pancreatic adenocarcinoma, surgically
harvested tissues are often used to collect data and perform genomic analysis to
identify driver oncogenes and specific mutations, or to quantify a handpick of
(micro)RNAs and proteins biomarkers. However, such strategy raises many concerns
not only because 80% of patients diagnosed with pancreatic adenocarcinoma are not
eligible for surgery, meaning that biopsies are not collected, but also because repeated
core biopsies are related to higher risk of morbidity, are expensive and logistics can
be limiting. Alternative sample collection methods include fine-needle aspirates
(FNA) collected under endoscopic ultrasound (EUS). In this chapter, we will describe
how EUS-FNA material can be a wealthy source of biomarkers for pancreatic cancer
patient management. In greater details, we will review how DNA, micro(RNA), or
protein analysis can help stratify pancreatic adenocarcinoma patients, from single
events analysis, to cutting-edge, high-throughput studies.
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1. Introduction
Tissue biopsies are required for diagnosis, prognosis, and to measure individual drug response
markers for patient management. For pancreatic adenocarcinoma, surgically harvested tissues
are often used to collect data and perform genomic analysis to identify driver oncogenes and
specific mutations, or to quantify a handpick of (micro)RNAs and proteins biomarkers.
However, such strategy raises many concerns not only because 80% of patients diagnosed with
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pancreatic adenocarcinoma are not eligible for surgery, meaning that biopsies are not collected,
but also because repeated core biopsies are related to higher risk of morbidity, are expensive
and logistics can be limiting. Alternative sample collection methods include fine-needle
aspirates (FNA) collected under endoscopic ultrasound (EUS). In this chapter, we will describe
how EUS-FNA material can be a wealthy source of biomarkers for pancreatic cancer patient
management. In greater details, we will review how DNA, micro(RNA), or protein analysis
can help stratify pancreatic adenocarcinoma patients, from single events analysis, to cutting-
edge, high-throughput studies.
2. Fine-needle aspirates for pancreatic cancer diagnosis and prognosis
Pancreatic cancer remains one of the most deadly types of tumor. The five-year survival rate
after diagnosis is less than 3.5% [1]. Only 15% of pancreatic ductal adenocarcinoma (pancreatic
cancer) patients can be diagnosed at a resectable and possible curative stage. The remaining
patients diagnosed with locally advanced and/or metastatic tumors are treated in a palliative
way. Single-agent gemcitabine, although not dramatically improving survival, has demon‐
strated a significant clinical benefit and has become the standard chemotherapy for advanced
pancreatic cancer [2]. Recently, FOLFIRINOX protocol and association gemcitabine-Nab-
paclitaxel regimens were found to improve the survival of metastatic patients when compared
to gemcitabine alone [3, 4]. However, median survival does not exceed six and ten months for
metastatic and locally advanced pancreatic cancer, respectively [5]. One way to improve
pancreatic cancer management is to establish a rapid and clear diagnosis in order to operate
or to start a medical treatment as soon as possible. One of the critical clinical conditions is the
differentiation of pancreatic cancer from focal pancreatitis. It is indeed necessary to avoid
unnecessary resection of benign lesions (such chronic pancreatitis in its pseudotumoral form
or autoimmune pancreatitis) or to delay the treatment of pancreatic cancer in a subset of
patients. Recent advances in abdominal imaging techniques may favor a more rapid histolog‐
ical diagnosis and also may resolve some of these problems of differential diagnosis. Among
these imaging techniques, endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)
is a rapid, safe, cost-effective, and accurate technique for evaluating and staging pancreatic
tumors [6–8]. EUS allows to guide FNA of solid pancreatic lesions for cytopathological
analysis. However, its performance for the diagnosis of malignancy varies widely with a
sensitivity ranging from 75–94% and an accuracy of 78–95%. In addition, if the specificity
approaches 100%, its negative predictive value ranges from 40–75%. In addition, EUS-FNA
may be inconclusive in up to 20% of cases [8, 9]. Overall, false-negative rates and atypical or
suspicious diagnoses remain relatively frequent using cytopathological analysis [9]. The
improvement of molecular biology techniques, including DNA and RNA amplification,
permits the analysis and quantification of molecular markers in cytological samples. In
addition, EUS-FNA is the main clinical appliance for cytological and histological material
collection from locally advanced pancreatic cancer that represents 85% of pancreatic cancer
patients. This chapter depicts the widespread potential for the molecular analysis of samples
obtained by EUS-FNA in conducting translational studies to improve knowledge and diag‐
nosis of pancreatic cancer.
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3. Identification of key mutations in tumor suppressor genes and
oncogenes using FNA material
We and others have demonstrated that DNA extracted from EUS-FNA material may permit
to detect single DNA mutations in key tumor suppressor genes and oncogenes for better
pancreatic cancer patients management (for review [6]). The next challenge is to identify new
technologies that are more sensitive than standard quantitative PCR (qPCR) or that may allow
screening of multiple mutations in a few nanograms of DNA. Recently, digital PCR (dPCR)
has shown promise in cancer diagnosis, although current dPCR systems have lower through‐
put than qPCR systems. dPCR is based on absolute nucleic acid quantification following
partitioning of individual molecules into multiple replicate reactions at limiting dilution.
Following reaction, the starting concentration of template is determined by Poisson statistical
analysis of the number of positive (with amplified target) and negative (without amplified
target) detected reactions [10]. By essence, dPCR is anticipated to be more tolerant to PCR
inhibitors by virtue of being an end-point approach; with improved amplification efficiency
and, thus, sensitivity. Accordingly, Hindson et al. recently compared the performance of dPCR
to real-time PCR in clinical specimens. When applied to serum microRNA biomarker analysis,
dPCR was proved to provide superior diagnostic performance for identifying individuals with
cancer than qPCR [10]. Similar results have been reported in a small cohort of patients with
pancreatic cancer. Dr Capella’s group recently demonstrated that digital PCR provides a
robust and quantitative assay for KRAS mutant alleles detection in routinely obtained samples
[11]. The next objective is to transfer this approach to the screening of DNA mutations in
material from EUS-FNA.
Large pancreatic cancer sequencing initiatives are revealing a vast array of molecular aberra‐
tions in histologically indistinguishable tumors (for review [12]). Of importance, the muta‐
tional burden seems to be particularly heterogeneous and this has major implications in
therapeutic development and clinical care. Indeed, better understanding the genetic and
molecular basis of cancer may not only help to stratify patients but also develop new classes
of therapies that selectively target molecular mechanisms that are essential for the survival
and proliferation of cancer cells. Unfortunately, such analysis requires amounts of material
that are out of reach following EUS-FNA. Alternatively, targeted next-generation sequencing
(NGS) can be performed with minimal amount of DNA. One of these approaches is based on
the Ion Torrent Ampliseq technology. In thyroid cancer, 5–10 ng of input DNA is sufficient for
the successful analysis of virtually all samples, either thyroid tissue or fine-needle aspiration
samples, and revealed point mutations in specific types of thyroid cancer [13]. We recently
translated this method to the analysis of FNA material from pancreatic tumors; we found that
this approach is feasible with minimal amount of DNA. Using the comprehensive cancer panel,
we verified KRAS mutation and discovered new mutations in key oncogenic drivers and tumor
suppressor genes that are currently validated by qPCR. Thus, targeted NGS holds great
promise for pancreatic cancer patient stratification and management.
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4. Quantification of microRNA in FNA material
Beside DNA, microRNAs are well-characterized biomarkers for pancreatic cancer manage‐
ment (for review [14]). To date, most studies are limited to the quantification of a handful of
selected candidate microRNAs in EUS-FNA material. For example, Dr Szafranska’s group
recently validated a 5-miRNA expression classifier to improve preoperative detection of
pancreatic cancer [15]. While these results are encouraging, further developments are needed
to analyze simultaneously several dozens of microRNA in EUS-FNA material. Current
methods for the detection and measurement of microRNA expression include the abovemen‐
tioned standard quantitative PCR and microarray based analysis. However, these methods
suffer several limitations when used in large clinical studies where a high-throughput and
highly quantitative technology is needed for the efficient characterization of a large number
of microRNA transcripts in clinical samples. Recently, high-throughput qPCR-based micro‐
fluidic technology (Biomark Fluidigm) has been evaluated to quantify microRNA expression
in lung cancer [16]. The authors demonstrate that (1) the technic is highly reproducible, (2)
multiplex results correlate closely with singleplex qPCR, (3) throughput is 5–20 times higher,
and (4) cost is approximately 50–100 times lower than conventional assays [16]. We recently
benchmarked and validated this approach for the analysis of 96 candidate microRNAs in EUS-
FNA material from pancreatic cancer patients, starting from 200 ng of total RNA (Fig. 1). In
addition, we found that amplification quality was greater when using material collected from
FNA and conserved in RNA later, as compared to material extracted from archived slides
(personal observation).
While the measurement of microRNA expression in rare cell populations or in precious
samples such as FNA still poses practical challenges due to the low amount of RNA present,
alternative techniques have been developed to quantify the complete microRNA landscape in
less than 50 ng of total RNA. Such highly sensitive real-time quantitative PCR strategy utilizes
microfluidic array cards containing prespotted TaqMan probes that allows the detection of
mature miRNAs in small reaction volumes. This approach, namely OpenArray® MicroRNA
Panels, was used for the characterization of microRNA expression in mouse hematopoietic
stem cells [17]. We have recently validated this approach for the detection and quantification
of circulating microRNA in patients (Buscail et al., Molecular Therapy, in press); similar
experiments are currently ongoing to characterize the microRNA pattern of expression in EUS-
FNA material from patients with pancreatic cancer.
5. Multiplexed protein analysis in FNA material
EUS-FNA has been proven as a useful method for diagnosing pancreatic lesions and is
associated with high accuracy in moderately to poorly differentiated pancreatic cancer.
However, diagnosis of well-differentiated cancer or early stage tumors can be challenging; in
these situations, an indeterminate diagnosis is often rendered. Ancillary stains can provide
much needed supportive evidence. Many studies have used a large number of stains to
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document an immunohistochemical profile of pancreatic cancer [18–25], but the number of
proteins than can be analyzed is often limiting. Recently, multiplexed flow cytometry and mass
cytometry have been proposed to examine an expanded set of markers (up to 50). However,
flow cytometry is often limited by the number of markers that can be analyzed due to spectral
overlap. Also, mass cytometry requires cells to be vaporized during sample preparation,
resulting in sample loss [26]. Very recently, Ullal et al. designed a remarkable strategy based
on antibody barcoding with photocleavable DNA platform to perform multiplexed protein
measurements in small amounts of clinical sample material [27]. This method showed high
reproducibility and achieved single-cell sensitivity. Using this strategy, the authors success‐
fully analyzed the expression of 90 candidate proteins and demonstrated that this method
could be used to identify pathway responses to molecularly targeted drugs in FNA, to help
predict drug response in patients with lung cancer [27]. While technically challenging, it is
tempting to speculate that this approach will be soon translated to the analysis of EUS-FNA
material from patients with pancreatic cancer.
Figure 1. qPCR-based microfluidic analysis of microRNA expression in pancreatic tumors FNA. Unpublished results.
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6. Future development: Defining pancreatic tumors heterogeneity at the
cellular level
As stated before, large-scale genomic studies on pancreatic tumors revealed marked inter- and
intratumoral heterogeneity and complexity, and may explain the lack of success of conven‐
tional, disease-based approaches, therapies. A better understanding of the underlying
molecular pathology at the cellular level may undoubtedly lead to novel therapeutics devel‐
opment. Indeed, many biological programs are performed under the assumption that all cells
of a particular type are identical. However, recent data suggest that individual cells within a
single population may differ quite significantly and these differences can drive the health and
function of the entire cell population, including major variation in the tumor cell microenvir‐
onment. Single cell analysis comprises a broad field that covers advanced optical, electro‐
chemical, mass spectrometry instrumentation, and sensor technology, as well as separation
and sequencing techniques. Although the approaches currently in use can offer snapshots of
single cells, the methods are often not amenable to longitudinal studies that monitor changes
in individual cells in situ. Recently, David Ting et al., from Dr Harber’s group in Harvard, have
performed epitope-independent microfluidic capture, followed by single-cell RNA sequenc‐
ing, to analyze circulating pancreatic tumor cells (CTCs) in experiment models [28]. The
authors demonstrate that CTCs exhibit a very high expression of stromal-derived extracellular
matrix proteins, including SPARC, a tentative prognosis marker for nab-paclitaxel-based
therapy. At present, the clinical use of single-cell analysis is – with the exception of preim‐
plantation diagnosis – still in its infancy. However, we are facing an era of integrated single-
cell genomic, epigenomic, transcriptomic, and proteomic analysis that will revolutionize
whole-organism science. Single-cell diagnostics will be instrumental for the realization of
personalized medicine for pancreatic cancer patients and for the development of completely
novel therapeutic concepts.
7. Conclusion
At present, the classification of tumors is mainly based on observational characteristics, such
as morphology, phenotype, or developmental origin. The current progress in developing
sophisticated approaches for investigating EUS-FNA material will definitely improve our
understanding of pancreatic cancer at multiple levels, through (1) a better definition of cell
types and intercellular variability, (2) a possibility to carry large-scale mutational, transcrip‐
tomic, or epigenomic analyses, and (3) an improved identification of rare cell types, to play an
increasing role in the detection of minimal residual disease or in the analysis of circulating
tumor cells. Accordingly, there are existing opportunities for more rapid improvement in
outcomes by adopting a more stratified or personalized approach using markers from different
molecular species. However, these progresses will have to complain not only with the
development of new drugs but also with clinical care and regulatory agencies. Nonetheless, it
is tempting to speculate that EUS-FNA-based molecular evidences will soon drive decision
making for patients with advanced pancreatic cancer.
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